Somaxon Could Seek Buyer For Silenor Sleep Aid, OTC Marketing Rights
By
Elizabeth Crawford / Email the Author / “The Tan Sheet” Jan. 2, 2012, Vol. 20, No. 01
Rx-to-OTC Switch / Word Count: 1160 / Article # 05120102003
Executive Summary
Somaxon reconsiders its options and might sell the sleep aid Silenor, despite a “clear path” to switch OTC, after the firm’s stock fell from $10.60 per share to 42 cents per share. Procter & Gamble would have first crack at exclusive OTC marketing rights if Somaxon sells Silenor.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.